StockMarketWire.com - Ixico has narrowed its FY pretax loss to GBP1.4m, from a loss of GBP2.5m for the preceding 16-month period. Revenue was GBP3.1m, from GBP3.4m.

"I am delighted to report growth in our clinical trials service business and excellent progress in developing strategic partnerships with pharmaceutical companies using our digital technology platform, generating new and larger contracts," said CEO Derek Hill.




At 10:07am: [LON:IXI] IXICO plc share price was -1.5p at 29p



Story provided by StockMarketWire.com